Provenge for prostate cancer

Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The recommended course of therapy for Provenge (sipuleucel-T) is three complete doses, given at approximately 2-week intervals. NCCN recommends it for non-symptomatic disease of when life expectancy is greater that 6 months; for other cases it recommends docetaxel.
On April 29, 2010, the FDA approved Provenge as follows: PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. 

http://www.bcbs.com/blueresources/tec/vols/24/special-report-vaccines-for.html

Provenge (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation; April 2010.

Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T Immunotherapy for Castration-resistant Prostate Cancer. N Engl J Med. 2010;363:411-422.

nccn.org.prostate, PROS-9

Comments

[Morristown Cancert treatment]

The traditional method of confirming the presence of prostate cancer is a biopsy, by which a tiny portion of a patient's prostate is removed and examined for cancerous growths. Once the disease is detected, it is crucial to find out how far it has spread. Once cancer is confirmed, the decision needs to be made whether some kind of treatment is needed right away.